Jeffrey Dierks Sells 13,125 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 13,125 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $37.31, for a total transaction of $489,693.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Jeffrey Dierks also recently made the following trade(s):

• On Monday, January 27th, Jeffrey Dierks sold 1,629 shares of Harmony Biosciences stock. The shares were sold at an average price of $38.02, for a total transaction of $61,934.58.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total value of $388,864.07.

Harmony Biosciences Price Performance

Shares of HRMY opened at $38.82 on Thursday. The company has a market cap of $2.21 billion, a P/E ratio of 18.40, a PEG ratio of 0.51 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The firm’s 50 day moving average price is $35.20 and its 200 day moving average price is $35.22.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company’s revenue was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. On average, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HRMY. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a research note on Monday. Cantor Fitzgerald increased their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Monday, January 13th. Oppenheimer restated an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Finally, Raymond James reiterated an “outperform” rating and issued a $40.00 target price on shares of Harmony Biosciences in a report on Thursday, October 10th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $55.00.

Institutional Investors Weigh In On Harmony Biosciences

Several large investors have recently bought and sold shares of the stock. Legato Capital Management LLC increased its stake in shares of Harmony Biosciences by 26.0% during the fourth quarter. Legato Capital Management LLC now owns 26,720 shares of the company’s stock worth $919,000 after buying an additional 5,506 shares during the period. Louisiana State Employees Retirement System grew its holdings in Harmony Biosciences by 26.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 18,500 shares of the company’s stock worth $637,000 after acquiring an additional 3,900 shares in the last quarter. Polaris Capital Management LLC increased its position in shares of Harmony Biosciences by 29.6% in the 4th quarter. Polaris Capital Management LLC now owns 58,300 shares of the company’s stock valued at $2,006,000 after purchasing an additional 13,300 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Harmony Biosciences by 6.2% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 47,700 shares of the company’s stock valued at $1,641,000 after purchasing an additional 2,800 shares in the last quarter. Finally, Hedeker Wealth LLC lifted its position in shares of Harmony Biosciences by 1.2% during the 4th quarter. Hedeker Wealth LLC now owns 76,203 shares of the company’s stock worth $2,622,000 after purchasing an additional 916 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.